AstraZeneca (AZN) Tops Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
Go back to AstraZeneca (AZN) Tops Q3 EPS by 6c
November 10, 2016 6:56 AM EST
By Ben Hirschler
LONDON (Reuters) - Drugmaker AstraZeneca (NYSE: AZN) expects major U.S. healthcare changes after Donald Trump's election victory but its chief executive warned on Thursday that pricing pressures in the world's biggest drugs market would not go away.
Drug stocks surged on Trump's surprise win as fears of tough action on prices subsided, given the Republican president-elect's focus on scrapping Obamacare rather than bearing down hard on drugmakers as Democrats demanded.
"Nobody knows what the new landscape will look like. It's reasonable to assume it will change substantially,"... More
November 9, 2016 12:03 PM EST
Donald Trump's victory not only shocked the world but shocked the market. Below are all the sectors and stocks being impacted by his victory:
Biotech (Positive): Trump is viewed as less onerous than Clinton on drug pricing.
Gilead Sciences (NASDAQ:
GILD) +4.5%Celgene (NASDAQ:
CELG) +8.5%XBI (NYSE:
XBI) is up 7%IBB (NYSE:
IBB) is up 6.6%Alexion Pharmaceuticals (NASDAQ:
ALXN)...
More
